Preview

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

Advanced search

PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY)

https://doi.org/10.17749/2070-4909.2016.9.4.014-023

Full Text:

Abstract

Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as an important problem that can lead to cirrhosis and hepatic failure. It may be the most prevalent liver disease. However, knowledge of the epidemiology is limited. These findings encourage to conduct a larger sample size study to evaluate the real prevalence of NAFLD in the Russian population. It is important to know current prevalence of NAFLD. DIREG 2 study was performed under umbrella of leading Russian professional societies in partnership with Sanofi Russia.

Objective: to estimate the prevalence of NAFLD within the general practitioners and gastroenterologist’s patient flow. It is important to know current prevalence of NAFLD in Republic of Bashkortostan and to compare with DIREG 2 results.

Materials and methods. Epidemiologic, observational, multicenter study assessing the prevalence of NAFLD among patient’s outpatient practice. A total of 50145 patients (3232 in Republic of Bashkortostan) including those suspected of having NAFLD criteria were enrolled in the Program. The investigators were qualified doctors (GPs/therapist’s/gastroenterologists), providing outpatient care for the population. The epidemiological data were obtained, recorded during two routine patient visits to investigating centers.

Results. Percentage of patients with revealed NAFLD within the patient flow primary or
consistently coming to selected doctors for any reason including those suspected of having NAFLD was 37,3% in Russia vs 40,8% in Republic of Bashkortostan.

Conclusion. Prevalence of NAFLD among patient flow of doctors in Russia is quite high. It has been revealed a high prevalence of NANCFLD within the patient flow primary or consistently coming to selected by doctors for any reason.

About the Authors

D. Kh. Kalimullina
Bashkir State Medical University
Russian Federation

Chief specialist in clinical pharmacology, Ministry of Health, Republic of Bashkortostan. Bashkir State Medical University. Address: ul. Lenina, 3, Ufa, Respublika Bashkortostan, Russia, 450000



A. S. Yurkina
FSBEI HE I. M. Sechenov First MSMU MOH Russia
Russian Federation

MD, State Federal-Funded Educational Institution of Higher Professional Training I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. Address: ul. Trubetskaya, 8-2, Moscow, Russia, 119991. Tel.: +7(495)6091400



T. I. Ushakova
LLC “KM Practice”
Russian Federation
CM Practice LLC


D. V. Blinov
FSBE HE N. I. Pirogov RNRMU MOH Russia
Russian Federation

MD, PhD, Pirogov Russian National Research Medical University (RNRMU). Address: ul. Ostrovitianova, 1, Moscow, Russia, 117997



References

1. Bokeriya L. A. i dr. Byulleten’ NTsSSKh im. AN Bakuleva RAMN. 2007; 8 (5): 5-11.

2. Drapkina O. M., Korneeva O. N., Ivashkin V. T. Lechashchii vrach. 2010; 2: 43-45.

3. Drapkina O. M., Ivashkin V. T. RZhGGK. 2014; 4: 32-38.

4. Ivashkin V. T., Maevskaya M. V, Pavlov Ch. S., Shirokova E. N., Bueverov A. O., Drapkina O. M., Shul’pekova Yu. O., Tsukanov V. V., Mammaev S. N., Pal’gova L. K., Tikhonov I. N. Diagnosis and treatment of nonalcoholic fatty liver disease [Diagnostika i lechenie nealkogol’noi zhirovoi bolezni pecheni. Metodicheskie rekomendatsii dlya vrachei. ROPIP (in Russian)]. Moscow. 2015. URL: http://www.rsls.ru/files/Guidelines-RSLS-NASH- 2016-01-03.pdf. Accessed: 13.03.2016.

5. Ivashkin V. T., Maevskaya M. V. Ros zhurn gastroenterol gepatol koloproktol. 2010; 1: 4-13.

6. Ivashkin V. T. i soavt. Rossiiskie meditsinskie vesti. 2014; 4: 82-91.

7. Ivashkin V. T., Drapkina O. M., Maev I. V., Trukhmanov A. S., Blinov D. V., Pal’gova L. K., Tsukanov V. V., Ushakova T. I. RZhGGK. 2015; 6: 31-41.

8. Ignat’eva V. I., Avksent’eva M. V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2014; 3: 3-11.

9. Korneeva O. N., Drapkina O. M. Ros. zhurn. gastroenterol., gepatol., koloproktol.. 2007; 1 (17): 65.

10. Lazebnik L. B., Zvenigorodskaya L. A. Metabolic syndrome and digestive organs [Metabolicheskii sindrom i organy pishchevareniya (in Russian)]. Moscow. 2009; 182 s.

11. Lipatova L. V. pilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 20-27.

12. Makarov I. O., Borovkova E. I., Kazakov R. D. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2012; 4: 18-21.

13. Makarov I. O., Pavlov Ch. S., Shemanaeva T. V., Voevodin S. M., Muravei A. Yu. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2013; 1: 22-25.

14. Mamedov M. N., Oganov R. G. Profilaktika zabolevanii i ukreplenie zdorov’ya. 2005; 8 (6): 41-45.

15. Odinak M. M., Bazilevich S. N., Dyskin D. E., Prokudin M. Yu. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 45-50.

16. Polivanov V. A. FARMAKOEKONOMIKA. Sovremennaya farmako-ekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2009; 1: 7-11.

17. Tsukanov V. V., Tonkikh Yu. L., Kasparov E. V. et al. Vrach. 2010; 9: 1-4.

18. Shul’pekova Yu. O. Farmateka. 2007; 141 (6): 48-53.

19. Aithal G. P., Das K., Chowdhury A. Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD). GI Epidemiology: Diseases and Clinical Methodology, Second Edition. 2014; 357-372.

20. Alberti K. G., Zimmet P., Shaw J.; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet. 2005; 366 (9491): 1059-1062.

21. Anfossi G., Massucco P., Bonomo K., Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr. Metab. Cardiovasc. Dis. 2004; 14: 215-224.

22. Argo S. K., Loria P., Caldwell S. H., Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008; 48 (2): 662-669.

23. Browning J. S., Szczepaniak L. S., Dobbings L. S., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40 (7): 1387-95.

24. Brunt E. M. Nonalcoholic steatohepatiatis. Semin Liver Dis. 2004; 24: 3-20.

25. Clark J. M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006; 40: 5-10.

26. De Alwis N. M., Day C. P. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008; 48 (1): 104-112.

27. de Denus S., Spinier S. A., Miller K. Statins and liver toxicity: a meta-analysis. Pharmactiherapy. 2004; 24 (5): 584-591.

28. Drapkina O., Evsyutina Y., Ivashkin V. Prevalence of non-alcoholic fatty liver disease in the Russian Federation: the open, multicenter, prospective study, DIREG 1. American Journal of Clinical Medicine Research. 2015; 3 (2): 31-36.

29. Drapkina O. M., Ivashkin V. T. Liver disease structure explored in Russian Federation: national-wide DIREG-L-01903 study for non-alcoholic fatty liver disease screening. Journal of Hepatology. 2011; 54: 332.

30. Forse R. A., Krishnamurty D. M. Epidemiology and Discrimination in Obesity. The ASMBS Textbook of Bariatric Surgery. Springer New York. 2015; 3-12.

31. Goland S. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. Journal of clinical gastroenterology. 2006; 40 (10): 949-955.

32. Grundy S. M., Cleeman J. I., Daniels S. R. et al.; American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association / National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 112 (17): 2735-2752.

33. Gundermann K. J., Kuenker A., Kuntz E., Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011; 63: 643-659.

34. Hamaguchi M., Kojima T., Takeda N. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13: 1579-84.

35. Haring R., Wallaschofski H., Nauck M., Dцrr M., Baumeister S. E., Vцlzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. Hepatology. 2009; 50: 1403-11.

36. Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow. United European Gastroenterology Journal. 2015; 3 (1): 344-345.

37. Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow. UEG Week 2015. UEG15-ABS-3697.

38. Lazo M., Hernaez R., Bonekamp S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011; 343: d6891.

39. Ludwig J., Viggiano T. R., McGill D. B., Oh B. J. Nonalcoholic steatohepati-tis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434-438.

40. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A. J., Natale S., Forlani G., Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50: 1844-50.

41. McCullough A. J. Epidemiology of the metabolic syndrome in the USA. Journal of digestive diseases. 2011; 12 (5): 333-340.

42. Neuschwander-Tetri B. A., Caldwell S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37: 1202-19.

43. Nomura H., Kashiwaqi S., Hayashi J., et al. Prevalence of fatty liver in a general population of Okinawa Japan. Jap J Med. 1998; 27 (1): 142-9.

44. Picardi A., Vespasiani-Gentilucci U. Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass. Am J Gastroenterol. 2008; 103: 3036-8.

45. Sanyal A. J., Banas C., Sargeant C., Luketic V. A., Sterling R. K., Stravitz R. T., et al. Similarities and differences in outcomes of cirrhosis due to non-alcoholic steatohepatitis and hepatitis C. Hepatology. 2006; 43: 682-689.

46. Schwimmer J. B. et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006; 118 (4): 1388-1393.

47. Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. Journal of hepatology. 2008; 49 (4): 600-607.

48. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non- alcoholic fatty liver disease: causal effect or epiphenome-non? Diabetologia. 2008; 51: 1947-1953.


For citation:


Kalimullina D.K., Yurkina A.S., Ushakova T.I., Blinov D.V. PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY). PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2016;9(4):14-23. (In Russ.) https://doi.org/10.17749/2070-4909.2016.9.4.014-023

Views: 260


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)